Literature DB >> 22017875

mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR.

Daming Gao1, Hiroyuki Inuzuka, Meng-Kwang Marcus Tan, Hidefumi Fukushima, Jason W Locasale, Pengda Liu, Lixin Wan, Bo Zhai, Y Rebecca Chin, Shavali Shaik, Costas A Lyssiotis, Steven P Gygi, Alex Toker, Lewis C Cantley, John M Asara, J Wade Harper, Wenyi Wei.   

Abstract

The activities of both mTORC1 and mTORC2 are negatively regulated by their endogenous inhibitor, DEPTOR. As such, the abundance of DEPTOR is a critical determinant in the activity status of the mTOR network. DEPTOR stability is governed by the 26S-proteasome through a largely unknown mechanism. Here we describe an mTOR-dependent phosphorylation-driven pathway for DEPTOR destruction via SCF(βTrCP). DEPTOR phosphorylation by mTOR in response to growth signals, and in collaboration with casein kinase I (CKI), generates a phosphodegron that binds βTrCP. Failure to degrade DEPTOR through either degron mutation or βTrCP depletion leads to reduced mTOR activity, reduced S6 kinase activity, and activation of autophagy to reduce cell growth. This work expands the current understanding of mTOR regulation by revealing a positive feedback loop involving mTOR and CKI-dependent turnover of its inhibitor, DEPTOR, suggesting that misregulation of the DEPTOR destruction pathway might contribute to aberrant activation of mTOR in disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017875      PMCID: PMC3229299          DOI: 10.1016/j.molcel.2011.08.030

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  38 in total

Review 1.  The DNA damage response: ten years after.

Authors:  J Wade Harper; Stephen J Elledge
Journal:  Mol Cell       Date:  2007-12-14       Impact factor: 17.970

2.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

3.  Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids.

Authors:  Yasemin Sancak; Liron Bar-Peled; Roberto Zoncu; Andrew L Markhard; Shigeyuki Nada; David M Sabatini
Journal:  Cell       Date:  2010-04-08       Impact factor: 41.582

4.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.

Authors:  Andrew Y Choo; Sang Gyun Kim; Matthew G Vander Heiden; Sarah J Mahoney; Hieu Vu; Sang-Oh Yoon; Lewis C Cantley; John Blenis
Journal:  Mol Cell       Date:  2010-05-28       Impact factor: 17.970

5.  mTOR and cancer: many loops in one pathway.

Authors:  Alejo Efeyan; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2009-11-27       Impact factor: 8.382

6.  Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.

Authors:  Daming Gao; Hiroyuki Inuzuka; Alan Tseng; Rebecca Y Chin; Alex Toker; Wenyi Wei
Journal:  Nat Cell Biol       Date:  2009-03-08       Impact factor: 28.824

7.  New insights into mTOR signaling: mTORC2 and beyond.

Authors:  Dario R Alessi; Laura R Pearce; Juan M García-Martínez
Journal:  Sci Signal       Date:  2009-04-21       Impact factor: 8.192

8.  ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery.

Authors:  Chang Hwa Jung; Chang Bong Jun; Seung-Hyun Ro; Young-Mi Kim; Neil Michael Otto; Jing Cao; Mondira Kundu; Do-Hyung Kim
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

9.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).

Authors:  Juan M García-Martínez; Dario R Alessi
Journal:  Biochem J       Date:  2008-12-15       Impact factor: 3.857

10.  Cdh1 regulates cell cycle through modulating the claspin/Chk1 and the Rb/E2F1 pathways.

Authors:  Daming Gao; Hiroyuki Inuzuka; Michael Korenjak; Alan Tseng; Tao Wu; Lixin Wan; Marc Kirschner; Nicholas Dyson; Wenyi Wei
Journal:  Mol Biol Cell       Date:  2009-05-28       Impact factor: 4.138

View more
  135 in total

Review 1.  Regulation of autophagy by protein post-translational modification.

Authors:  Willayat Yousuf Wani; Michaël Boyer-Guittaut; Matthew Dodson; John Chatham; Victor Darley-Usmar; Jianhua Zhang
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

2.  Linking metabolism and cell cycle progression via the APC/CCdh1 and SCFβTrCP ubiquitin ligases.

Authors:  Shanshan Duan; Michele Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-15       Impact factor: 11.205

3.  Cell signalling: mTOR targets its own inhibitor.

Authors:  Katharine H Wrighton
Journal:  Nat Rev Mol Cell Biol       Date:  2011-11-09       Impact factor: 94.444

Review 4.  mTOR signaling in stem and progenitor cells.

Authors:  Delong Meng; Anderson R Frank; Jenna L Jewell
Journal:  Development       Date:  2018-01-08       Impact factor: 6.868

Review 5.  mTOR function and therapeutic targeting in breast cancer.

Authors:  Stephen H Hare; Amanda J Harvey
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

6.  Akt-mediated phosphorylation of XLF impairs non-homologous end-joining DNA repair.

Authors:  Pengda Liu; Wenjian Gan; Chunguang Guo; Anyong Xie; Daming Gao; Jianping Guo; Jinfang Zhang; Nicholas Willis; Arthur Su; John M Asara; Ralph Scully; Wenyi Wei
Journal:  Mol Cell       Date:  2015-02-05       Impact factor: 17.970

Review 7.  Translational implications of endothelial cell dysfunction in association with chronic allograft rejection.

Authors:  Sarah Bruneau; Johannes Wedel; Fadi Fakhouri; Hironao Nakayama; Leo Boneschansker; Daniel Irimia; Kevin P Daly; David M Briscoe
Journal:  Pediatr Nephrol       Date:  2015-04-24       Impact factor: 3.714

8.  XPLN is an endogenous inhibitor of mTORC2.

Authors:  Nidhi Khanna; Yimin Fang; Mee-Sup Yoon; Jie Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

9.  mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy.

Authors:  James K Ching; Sarita V Elizabeth; Jeong-Sun Ju; Caleb Lusk; Sara K Pittman; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

Review 10.  Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.

Authors:  Chuan-Ming Xie; Wenyi Wei; Yi Sun
Journal:  J Genet Genomics       Date:  2013-02-10       Impact factor: 4.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.